We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+37.81%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.66B
AUM Growth
+$539M
Cap. Flow
+$598M
Cap. Flow %
12.83%
Top 10 Hldgs %
41.2%
Holding
160
New
26
Increased
26
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
SEER icon
Seer Inc
SEER
+$372M
2
KRON
Kronos Bio
KRON
+$41.3M
3
SQZ
SQZ Biotechnologies Company
SQZ
+$41M
4
Z icon
Zillow
Z
+$38.7M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$71.8M
2
BABA icon
Alibaba
BABA
+$62.5M
3
MRNA icon
Moderna
MRNA
+$25.3M
4
STNE icon
StoneCo
STNE
+$21.2M
5
SRRK icon
Scholar Rock
SRRK
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 78.81%
2 Consumer Discretionary 9.12%
3 Miscellaneous 6.2%
4 Technology 2.01%
5 Communication Services 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YMAB
76
DELISTED
Y-mAbs Therapeutics
YMAB
$14.1M 0.3%
285,028
– –
AUPH icon
77
Aurinia Pharmaceuticals
AUPH
$2.14B
$13.8M 0.3%
1,000,000
– –
RNAC icon
78
Cartesian Therapeutics
RNAC
$238M
$13.6M 0.29%
150,000
– –
NTLA icon
79
Intellia Therapeutics
NTLA
$1.61B
$13.6M 0.29%
250,000
+60,000
+32% +$2.18M
HARP
80
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$13.3M 0.29%
80,000
– –
SGTX
81
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$13.3M 0.28%
+21,231
New +$9.63M
BMRN icon
82
CALL
BioMarin Pharmaceuticals
BMRN
$12.4B
$13.2M 0.28%
150,000
– –
OLMA icon
83
Olema Pharmaceuticals
OLMA
$871M
$12.5M 0.27%
+260,500
New +$12.2M
DHR icon
84
Danaher
DHR
$146B
$11.1M 0.24%
56,400
-28,200
-33% -$5.65M
IMUX icon
85
Immunic
IMUX
$144M
$10.7M 0.23%
70,000
-10,000
-13% -$1.8M
HOOK
86
DELISTED
HOOKIPA Pharma
HOOK
$10.5M 0.23%
94,962
+35,000
+58% +$3.78M
CYTK icon
87
Cytokinetics
CYTK
$9.55B
$10.4M 0.22%
+500,000
New +$9.14M
SPRO icon
88
Spero Therapeutics
SPRO
$65.2M
$9.7M 0.21%
500,000
-100,000
-17% -$1.56M
BRKR icon
89
Bruker
BRKR
$8.4B
$9.49M 0.2%
175,275
– –
APTX
90
DELISTED
Aptinyx Inc. Common Stock
APTX
$8.66M 0.19%
2,502,035
+1,000,000
+67% +$3.48M
EVLO
91
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$8.46M 0.18%
35,000
+11,250
+47% +$1.39M
APLT
92
DELISTED
Applied Therapeutics
APLT
$8.36M 0.18%
380,000
– –
SYRE icon
93
Spyre Therapeutics
SYRE
$7.93B
$8.22M 0.18%
41,800
– –
SYRS
94
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.14M 0.17%
75,000
+28,450
+61% +$2.6M
AAL icon
95
CALL
American Airlines Group
AAL
$8.49B
$7.88M 0.17%
500,000
– –
ALPN
96
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.47M 0.16%
593,030
– –
ARAV
97
DELISTED
Aravive, Inc. Common Stock
ARAV
$7.4M 0.16%
1,311,291
– –
MTCR
98
DELISTED
Metacrine, Inc. Common Stock
MTCR
$7.27M 0.16%
924,898
-384,615
-29% -$3.53M
CLDX icon
99
Celldex Therapeutics
CLDX
$2.99B
$7.01M 0.15%
+400,000
New +$7.2M
YI
100
111 Inc
YI
$29.3M
$6.95M 0.15%
100,000
+35,000
+54% +$2.37M
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2020 Portfolio in Review

As of Q4 2020, Artal Group held 160 positions worth $4.66B, up 13% from $4.12B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Artal Group deployed $598M of net new capital in Q4 2020, opening 26 new positions and adding to 26 existing holdings. Its largest new stake was Seer Inc: 5,840,911 shares worth $328M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 58% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was BioNTech, an estimated $71.8M trimmed.

  • Artal Group's largest Q4 2020 buy was Seer Inc: 5,840,911 shares worth $328M.
  • Artal Group added most to Zillow in Q4 2020, an estimated $38.7M increase.
  • Artal Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $71.8M.
  • Artal Group fully exited StoneCo in Q4 2020, selling an estimated $21.2M.
  • Artal Group's ten largest holdings make up 41% of its $4.66B portfolio in Q4 2020.
  • Artal Group opened 26 new positions and closed 30 in Q4 2020.
  • Artal Group's portfolio value rose 13% quarter-over-quarter to $4.66B.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.